<DOC>
	<DOCNO>NCT00345358</DOCNO>
	<brief_summary>The purpose phase IIIb study determine whether child receive 3-dose primary vaccination pneumococcal conjugate vaccine 6 month age , receive vaccine part catch-up immunization schedule . The immunogenicity , safety reactogenicity GSK Biologicals ' pneumococcal conjugate vaccine evaluate four different age group different schedule : &lt; 6 month age group : 3-dose primary vaccination + booster dose . 7 11 month age group : 2-dose primary vaccination + booster dose . 12 23 month age group : 2-dose vaccination ; booster dose . 24 month 5 year age group : 1-dose vaccination ; booster dose . Children 6 month age receive concomitantly DTPa-IPV/Hib vaccine .</brief_summary>
	<brief_title>Immunogenicity Safety Study GlaxoSmithKline ( GSK ) Biologicals ' 10-valent Pneumococcal Conjugate Vaccine</brief_title>
	<detailed_description>The Protocol Posting update order comply FDA Amendment Act , Sep 2007</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male female , include 912 week age time first vaccination &lt; 6 Mo group . 711 month age time first vaccination 711 Mo group . 1223 month age time first vaccination 1223 Mo group . 24 month 5 year time first vaccination &gt; = 24 Mo group . Subjects investigator believe parents/guardians comply requirement protocol Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . Born gestation period 36 42 week . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use entire study period agegroup . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/ administration vaccine foreseen study protocol period start one month end one month dose vaccine ( ) . Previous vaccination S. pneumoniae . History allergic disease reaction likely exacerbate component vaccine . History seizure ( criterion apply subject single , uncomplicated febrile convulsion past ) neurological disease . Acute disease time enrolment . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination A family history congenital hereditary immunodeficiency . Major congenital defect serious chronic illness . Administration immunoglobulins and/or blood product since birth plan administration entire study period .</criteria>
	<gender>All</gender>
	<minimum_age>9 Weeks</minimum_age>
	<maximum_age>60 Months</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Booster vaccination</keyword>
	<keyword>Catch-up vaccination</keyword>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
	<keyword>Pneumococcal disease</keyword>
</DOC>